 Dare Bioscience NASDAQ:DARE was downgraded by investment analysts at ValuEngine from a buy rating to a hold rating in a note issued to investors on Tuesday, ValuEngine reports. DARE has been the subject of several other research reports. Roth Capital reissued a buy rating and set a 4.00 target price on shares of Dare Bioscience ... 